Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib

Fig. 1

Generation of CAR T cells targeting FLT3 and NKG2DLs. A A schematic representation of the manufactured FLT3scFv/NKG2D-CAR lentiviral construct. SP, signal peptide; scFv, single-chain fragment variable; Hinge, hinge chain. B FLT3scFv (EB10) and NKG2D expression assessed by flow cytometry of GFP + -transfected 293 T cells (B-1) and GFP + CAR T cells (B-2). The histograms show staining with recombinant FLT3 protein + anti-His APC antibody or anti-human NKG2D antibody (blue) compared to staining with isotype (red). C FLT3scFv (EB10) and NKG2D expression assessed by real-time PCR in transfected 293 T cells (C-1) and CAR T cells (C-2) compared with untransfected 293 T cells and UTD cells, respectively. D Significant CAR T cell transfection efficiency indicated by the percentage of GFP+ cells determined by flow cytometry. E CD4 and CD8 subtypes of CAR T cells assessed by flow cytometry. The data shown are derived from three independent experiments with T cells from different donors. UTD, un-transduced CD3 + T cells; GFP, green fluorescent protein; SSH, side scatter height; APC, allophycocyanin; PE, phycoerythrin. * p < 0.05, **** p < 0.0001

Back to article page

Molecular Cancer

ISSN: 1476-4598